Progress in nasal drug delivery research based on biomaterials
Source abstract
Abstract
In recent years, nasal administration has gradually become a research hotspot and is considered a promising alternative to traditional delivery methods owing to its ease of use, avoidance of the first-pass effect, and ability to bypass the blood–brain barrier. The disadvantages of oral and parenteral administration have prompted the use of nasal drug delivery as a convenient alternative to systemic drug availability. However, the rapid clearance of drugs by the nasal mucosal cilia, the presence of different enzymes in the mucosa that affect drug stability, and the insufficient residence time of drugs in the cavum nasi limit the development of nasal administration. Development of effective drug formulations and novel nasal drug delivery devices is now a top priority. With continuous advancements in biotechnology and materials science, the shortcomings of nasal drug delivery have been gradually compensated for by biomaterials. This review highlights biomaterials used in nasal drug delivery and discusses their characteristics and advantages. In addition, this review presents the applications of biomaterials in nasal drug delivery proposed in recent years, especially for diseases related to the central nervous system. Because of their targeting characteristics, the drugs can directly reach the brain, which can enhance the drug utilization rate and reduce side effects. Finally, this review summarizes the latest progress in biomaterial-based nasal drug delivery research, highlighting current research deficiencies and future development directions.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Nasal Surgery and Airway Studies · Ocular Surface and Contact Lens
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Clinical Medical College/Affiliated Hospital of Jiujiang University 1 , No. 57 East Xunyang Road, Jiujiang 332005, Jiangxi,
Jiujiang Clinical Precision Medicine Research Center 2 , Jiujiang, Jiangxi,
Jiujiang Innovation Center of Biosensor Technology and Application, Jiujiang University 3 , Jiujiang, Jiangxi,
School of Mechanical and Intelligent Manufacturing, Jiujiang University 4 , Jiujiang, Jiangxi,
Funding
Nation Natural Science Foundation of China
References (100+)
Show source-provided references
1. Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders10.1016/j.apsb.2022.07.003 ↗
2. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies10.1016/j.apsb.2021.02.012 ↗
3. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer’s disease10.1016/j.ejpb.2019.12.014 ↗
4. Unraveling the role of chitosan for nasal drug delivery systems: A review10.1016/j.carpta.2023.100316 ↗
5. Drop to gate nasal drops attenuates sepsis-induced cognitive dysfunction10.1002/smll.202403564 ↗
6. Tailoring formulations for intranasal nose-to-brain delivery: A review on architecture physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa10.3390/pharmaceutics10030116 ↗
7. Advanced particulate carrier-mediated technologies for nasal drug delivery10.1016/j.jddst.2022.103569 ↗
8. Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson’s disease10.1016/j.jconrel.2023.04.021 ↗
9. Non-invasive delivery strategies for biologics10.1038/nrd.2018.183 ↗
10. Permeability issues in nasal drug delivery10.1016/s1359-6446(02)02452-2 ↗
11. Recent advances in polymeric drug delivery systems10.1186/s40824-020-00190-7 ↗
12. Recent developments in functionalized polymer nanoparticles for efficient drug delivery system10.1016/j.nanoso.2019.100397 ↗
13. The application of mucoadhesive chitosan nanoparticles in nasal drug delivery10.3390/md18120605 ↗
14. Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles10.1007/s13346-019-00622-5 ↗
15. Progress in nasal drug delivery systems10.1016/j.ijpharm.2021.120994 ↗
16. Intranasal drug delivery: An efficient and non-invasive route for systemic administration10.1016/j.pharmthera.2012.03.003 ↗
17. Intranasal drug delivery: Opportunities and toxicologic challenges during drug development10.1007/s13346-020-00891-5 ↗
18. Nose to brain transport pathways an overview: Potential of nanostructured lipid carriers in nose to brain targeting10.1080/21691401.2017.1420073 ↗
19. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis10.1016/j.jconrel.2018.12.049 ↗
20. A recent review on nasal microemulsion for treatment of CNS disorder10.22159/ijcpr.2017v9i4.20963 ↗
21. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics10.1016/j.ejpb.2018.05.009 ↗
22. Transnasal-brain delivery of nanomedicines for neurodegenerative diseases10.3389/fddev.2023.1247162 ↗
23. Advances in nasal drug delivery systems10.1016/b978-0-12-819712-7.00015-2 ↗
24. Chitosan and its derivatives for application in mucoadhesive10.3390/polym10030267 ↗
25. Chitosan interaction with stomach mucin layer to enhances gastric retention and mucoadhesive properties10.1016/j.carbpol.2024.121926 ↗
26. Nasal nanovaccines10.1016/j.ijpharm.2017.07.012 ↗
27. Multiple roles of chitosan in mucosal drug delivery: An updated review10.3390/md20050335 ↗
28. Thiolated chitosan as an improved bioadhesive polymer in drug delivery10.1016/B978-0-12-819336-5.00013-3 ↗
29. Development and evaluation of optimized thiolated chitosan proniosomal gel containing duloxetine for intranasal delivery10.1208/s12249-019-1484-y ↗
30. Cellulose: Fascinating biopolymer and sustainable raw material10.1002/anie.200460587 ↗
31. Nasal drug absorption from powder formulations: The effect of three types of hydroxypropyl cellulose (HPC)10.1016/j.ejps.2016.09.028 ↗
32. The enhancement of nasal drug absorption from powder formulations by the addition of sodium carboxymethyl cellulose10.1109/tnb.2016.2612682 ↗
33. Nasal absorption of macromolecules from powder formulations and effects of sodium carboxymethyl cellulose on their absorption10.1371/journal.pone.0159150 ↗
34. From crosslinking strategies to biomedical applications of hyaluronic acid-based hydrogels: A review10.1016/j.ijbiomac.2023.123308 ↗
35. A green-based approach for noninvasive skin rejuvenation: Potential application of hyaluronic acid10.1016/j.envres.2023.116467 ↗
36. Synthesis, characterization and evaluation of hyaluronic acid-based polymers for nasal delivery10.1016/j.ijpharm.2022.122496 ↗
37. Nasal spray formulations based on combined hyalurosomes and glycerosomes loading Zingiber officinalis extract as green and natural strategy for the treatment of rhinitis and rhinosinusitis10.3390/antiox10071109 ↗
38. Cyclodextrins10.1016/j.ijpharm.2012.06.055 ↗
39. Cyclodextrins: Structure, physicochemical properties and pharmaceutical applications10.1016/j.ijpharm.2017.11.018 ↗
40. Performance and toxicity of different absorption enhancers used in the preparation of Poloxamer thermosensitive in situ gels for ketamine nasal administration10.1080/03639045.2020.1750625 ↗
41. Nasal biocompatible powder of Geraniol oil complexed with cyclodextrins for neurodegenerative diseases: Physicochemical characterization and in vivo evidences of nose to brain delivery10.1016/j.jconrel.2021.05.020 ↗
42. Progress and opportunities in Gellan gum-based materials: A review of preparation, characterization and emerging applications10.1016/j.carbpol.2023.120782 ↗
43. Bacteriocin enterocin CRL35 is a modular peptide that induces non-bilayer states in bacterial model membranes10.1016/j.bbamem.2019.183135 ↗
44. Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for parkinsonism10.1016/j.ijbiomac.2020.06.261 ↗
45. Stimuli-responsive in situ gelling system for nose-to-brain drug delivery10.1016/j.jconrel.2020.07.044 ↗
46. Gellan gum in drug delivery applications10.1016/b978-0-12-817055-7.00006-6 ↗
47. Nose-to-brain delivery by nanosuspensions-based in situ gel for breviscapine10.2147/ijn.s265659 ↗
48. Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: In vitro characterisation studies10.1016/j.jconrel.2006.12.014 ↗
49. Pectin gel vehicles for controlled fragrance delivery10.1080/10717540590929966 ↗
50. Mucoadhesive properties of various pectins on gastrointestinal mucosa: An in vitro evaluation using texture analyzer10.1016/j.ejpb.2007.01.010 ↗
51. Chitosan/pectin/gum Arabic polyelectrolyte complex: Process-dependent appearance, microstructure analysis and its application10.1016/j.carbpol.2013.10.008 ↗
52. Mucosal drug delivery: Barriers, in vitro models and formulation strategies10.1016/s1773-2247(13)50055-4 ↗
53. Biomacromolecules as carriers in drug delivery and tissue engineering10.1016/j.apsb.2017.11.005 ↗
54. Determination of number-average aggregation numbers of bile salts micelles with a special emphasis on their oxo derivatives—The effect of the steroid skeleton10.1016/j.bbagen.2013.11.008 ↗
55. Absorption-enhancing effects of bile salts10.3390/molecules200814451 ↗
56. Interaction of polymers with bile salts – Impact on solubilisation and absorption of poorly water-soluble drugs10.1016/j.colsurfb.2022.113044 ↗
57. HO-1-u-1 model for screening sublingual drug delivery—Influence of pH, osmolarity and permeation enhancer10.1016/j.ijpharm.2008.11.010 ↗
58. Permeability enhancement techniques for poorly permeable drugs: A review10.7324/JAPS.2012.2705 ↗
59. Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study10.1038/s41598-019-53999-1 ↗
60. Nasal absorption of insulin: Enhancement by hydrophobic bile salts10.1073/pnas.82.21.7419 ↗
61. Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles10.3389/fphar.2018.01283 ↗
62. Self-assembly of bile salts and their mixed aggregates as building blocks for smart aggregates10.1016/j.cis.2023.102846 ↗
63. Delivery of acetaminophen to the central nervous system and the pharmacological effect after intranasal administration with a mucoadhesive agent and absorption enhancer10.1016/j.ijpharm.2020.120046 ↗
64. Polyarginine nanocapsules: A versatile nanocarrier with potential in transmucosal drug delivery10.1016/j.ijpharm.2017.07.001 ↗
65. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema10.2147/IJN.S205295 ↗
66. Poly-l-arginine predominantly increases the paracellular permeability of hydrophilic macromolecules across rabbit nasal epithelium in vitro10.1023/a:1022485816755 ↗
67. Arginine-coated nanoglobules for the nasal delivery of insulin10.3390/pharmaceutics15020353 ↗
68. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering10.3390/ijms15033640 ↗
69. Microfluidic preparation of PLGA composite microspheres with mesoporous silica nanoparticles for finely manipulated drug release10.1016/j.ijpharm.2020.120173 ↗
70. PLGA nanoparticles for nasal drug delivery10.1016/j.jddst.2024.105564 ↗
71. PLGA-based nanomedicine: History of advancement and development in clinical applications of multiple diseases10.3390/pharmaceutics14122728 ↗
72. Review of hybrid PLGA nanoparticles: Future of smart drug delivery and theranostics medicine10.1016/j.matdes.2020.108805 ↗
73. In vitro and in vivo comparison of curcumin-encapsulated chitosan-coated poly(lactic-co-glycolic acid) nanoparticles and curcumin/hydroxypropyl-β-cyclodextrin inclusion complexes administered intranasally as therapeutic strategies for Alzheimer’s disease10.1021/acs.molpharmaceut.0c00675 ↗
74. Current status of the new antiepileptic drugs in chronic pain10.3389/fphar.2016.00276 ↗
75. Lamotrigine loaded PLGA nanoparticles intended for direct nose to brain delivery in epilepsy: Pharmacokinetic, pharmacodynamic and scintigraphy study10.1080/21691401.2021.1939709 ↗
76. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery10.1016/j.addr.2004.09.004 ↗
77. PEG-derivatized dual-functional nanomicelles for improved cancer therapy10.3389/fphar.2019.00808 ↗
78. PEGylated nanocarriers: A promising tool for targeted delivery to the brain10.1016/j.colsurfb.2019.110770 ↗
79. Improved intranasal retentivity and transnasal absorption enhancement by PEGylated poly-l-ornithine10.3390/ph11010009 ↗
80. Nose-to-brain/spinal cord delivery kinetics of liposomes with different surface properties10.1016/j.jconrel.2022.03.017 ↗
81. Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases10.1016/j.biomaterials.2019.119657 ↗
82. Nanoemulgel as an approach to improve the biopharmaceutical performance of lipophilic drugs: Contemporary research and application10.1016/j.jddst.2022.103420 ↗
83. Quality by design approach for an in situ gelling microemulsion of Lorazepam via intranasal route10.1016/j.msec.2017.03.002 ↗
84. Topical gels of lidocaine HCl using cashew gum and Carbopol 940: Preparation and in vitro skin permeation10.1016/j.ijbiomac.2013.09.049 ↗
85. Nose-to-brain delivery of teriflunomide-loaded lipid-based carbopol-gellan gum nanogel for glioma: Pharmacological and in vitro cytotoxicity studies10.1016/j.ijbiomac.2020.11.047 ↗
86. Pluronic nanotechnology for overcoming drug resistance10.1007/978-981-10-5864-6 ↗
87. Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: In vitro drug release, cell cytotoxicity, and uptake studies10.2147/IJN.S15057 ↗
88. Advances in the therapeutic delivery and applications of functionalized Pluronics: A critical review10.1016/j.cis.2021.102563 ↗
89. Microspheres as nasal drug delivery systems10.1016/s0169-409x(97)00069-0 ↗
90. Mucoadhesive microspheres for nasal administration of cyclodextrins10.1080/10611860802556842 ↗
91. Updated insight into the characterization of nano-emulsions10.1080/17425247.2023.2154075 ↗
92. Nanoemulsions for ‘Nose-to-brain’ drug delivery10.3390/pharmaceutics11020084 ↗
93. Evidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles10.1039/c6nr07581a ↗
94. Strategies to obtain encapsulation and controlled release of small hydrophilic molecules10.3389/fbioe.2020.00437 ↗
95. Box-Behnken design optimization of mucoadhesive chitosan-coated nanoemulsions for rosmarinic acid nasal delivery—In vitro studies10.1016/j.carbpol.2018.07.054 ↗
96. Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion10.1016/j.ijpharm.2017.07.030 ↗
97. From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS)10.1080/17425247.2016.1218462 ↗
98. Microemulsions as delivery systems10.1016/j.cocis.2012.06.001 ↗
99. Methods for encapsulation of hydrophilic drugs in nanocarriers
100. Using microemulsions: Formulation based on knowledge of their mesostructure10.1021/acs.chemrev.0c00812 ↗